Inventiva CEO to Join Guggenheim Biotech Summit 2026 Fireside Chat
Event summary
- Inventiva CEO Andrew Obenshain to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026.
- Event will be held at the Lotte New York Palace in New York City.
- Inventiva leadership will also hold one-on-one meetings during the conference.
- Inventiva is focused on developing oral therapies for MASH and other diseases with significant unmet medical need.
- Company is evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH.
The big picture
Inventiva's participation in the Guggenheim Biotech Summit 2026 underscores its strategic focus on advancing its lead candidate, lanifibranor, through pivotal clinical trials. The event provides a platform for the company to engage with key stakeholders and highlight its progress in addressing the significant unmet medical need in MASH treatment. The biotech sector continues to see intense competition and regulatory scrutiny, making such high-profile engagements crucial for visibility and potential partnerships.
What we're watching
- Clinical Trial Progress
- The pace at which Inventiva advances its NATiV3 Phase 3 trial for lanifibranor will be critical for its strategic positioning in the MASH treatment market.
- Investor Sentiment
- How the fireside chat and one-on-one meetings impact investor confidence and potential funding or partnerships.
- Competitive Dynamics
- Whether Inventiva can differentiate itself from competitors in the rapidly evolving MASH treatment landscape.
Related topics